Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1006995

registered interest
date	14/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	AAT Deficiency
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when he plans a NHS service for alpha-1 to improve patients' access to coordinated multi-disciplinary clinical expertise, which was approved by the Department's Prescribed Specialised Services Advisory Group in March 2016, to commence.
tabling member constituency	Birkenhead
tabling member printed	Frank Field
uin	191307
answer	answer is ministerial correction date of answer 21/11/2018 answer text <p>The Specialised Respiratory Clinical Reference Group (CRG) is maintaining an oversight of the need to develop a service specification and selection of providers to offer specialised expertise and management advice for patients diagnosed with alpha1 antitrypsin deficiency (AATD).</p><p> </p><p>The CRG has recommended that NHS England wait until it is clear on the outcome of the National Institute for Health and Care Excellence (NICE) Highly Specialised Technologies evaluation of human alpha1-proteinase inhibitor for treating emphysema in adults with documented severe AATD [ID856] until this development is taken forward.</p><p> </p><p>NICE has not yet published final guidance and recently consulted on its draft guidance. NICE’s evaluation committee is due to meet again to consider its recommendations in spring next year. This is to enable the company that makes the alpha1-proteinase inhibitor to prepare and submit additional information for consideration by the committee.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 21/11/2018 14:39:19 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	478 label Biography information for Lord Field of Birkenhead

42268

registered interest
date	10/03/2014
answering body	Home Office
answering dept id	1
answering dept short name
answering dept sort name
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, when she plans to answer Questions tabled by the hon. Member for Birkenhead on 28 February 2014 for answer on 6 March 2014 on the Assisted Voluntary Return and Reintegration project.
tabling member constituency	Birkenhead
tabling member printed	Mr Frank Field
uin	191307
answer	answer is ministerial correction date of answer 27/03/2014 answer text <p>I answered questions 190276 and 190398 on 24 March 2014, Column 18W and Column 19W respectively. I apologise for the delay in responding.</p><p> </p><p> </p> answering member constituency Old Bexley and Sidcup answering member printed James Brokenshire question first answered 27/03/2014 12:00:00 answering member 1530 label Biography information for James Brokenshire
tabling member	478 label Biography information for Lord Field of Birkenhead